Dental management of patients at risk of osteochemonecrosis of the jaws: A critical review

Oral Diseases

Volumn 15, Issue 8, 2009, Pages 527-537

  Fedele, S ^a   Kumar, N ^a   Davies, R ^a   Fiske, J ^b   Greening, S ^c   Porter, S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ANEURIN BEVAN UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

Anatomic site, oncology; Bone and joints; Discipline, infectious diseases; Pathogenesis; Pathogenesis, wound healing

Indexed keywords

AMOXICILLIN; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; CHLORHEXIDINE; CLINDAMYCIN; METRONIDAZOLE;

ANTIBIOTIC PROPHYLAXIS; CHEMOTHERAPY; CLINICAL DECISION MAKING; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DENTAL CARE; DENTAL SURGERY; DRUG POTENCY; DRUG WITHDRAWAL; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; HUMAN; JAW OSTEONECROSIS; MOUTH HYGIENE; ORAL SURGERY; PERIODONTITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; DENTAL CARE FOR CHRONICALLY ILL; DIPHOSPHONATES; HUMANS; JAW DISEASES; NEOPLASMS; ORAL SURGICAL PROCEDURES; ORTHOGNATHIC SURGICAL PROCEDURES; OSTEONECROSIS; PATIENT CARE PLANNING;

EID: 70349954954     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2009.01581.x     Document Type: Review

References (59)

1. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 : 369 376.
2. Allegra A, Oteri G, Nastro E et al (2007). Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25 : 164 169.
3. Altman DG, Bland JM (1995). Absence of evidence is not evidence of absence. Brit Med J 311 : 485.
4. American Dental Association Council on Scientific Affairs (2006). Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137 : 1144 1150.
5. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, Cauley J et al (2008). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 66 : 1320 1321.
6. Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C (2008). Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44 : 1088 1089.
7. Baim S, Miller PD (2009). Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 24 : 561 574.
8. Bamias A, Kastritis E, Bamia C et al (2005). Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 : 8580 8587.
9. Barker K, Lowe D, Olujohungbe A, Low E, Rogers SN (2007). Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis. Br J Haematol 139 : 626 628.
10. Bell BM, Bell RE (2008). Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 66 : 1022 1024.
11. Berenson JR, Rosen LS, Howell A et al (2001). Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91 : 1191 1200.
12. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G (2008). Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 : 857 869.
13. Campisi G, Di Fede O, Musciotto A et al (2007). Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. Ann Oncol 18 : 168 172.
14. Craig JV, Smyth RL (2002). The evidence-based practice manual for nurses. Edinburgh : Churchill Livingstone.
15. Dannemann C, Grätz KW, Riener MO, Zwahlen RA (2007). Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 40 : 828 834.
16. Dimopoulos MA, Kastritis E, Bamia C et al (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 : 117 120.
17. Don-Wauchope AC, Cole DE (2009). The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clin Biochem 42 : 1194 1196.
18. Durie BG, Katz M, Crowley J (2005). Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 : 99 102.
19. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA for the American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw (2008). Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 139 : 1674 1677.
20. Fleisch H (1998). Bisphosphonates: mechanisms of action. Endocr Rev 19 : 80 100.
21. Fugazzotto PA, Lightfoot S (2006). Bisphosphonate associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Mass Dent Soc 55 : 5.
22. Fugazzotto PA, Lightfoot WS, Jaffin R, Kumar A (2007). Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol 78 : 1664 1669.
23. Grant BT, Amenedo C, Freeman K, Kraut RA (2008). Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 66 : 223 230.
24. Green JR (2004). Bisphosphonates: preclinical review. Oncologist 9 : s3 s13.
25. Hasmim M, Bieler G, Rüegg C (2007). Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5 : 166 173.
26. Hellstein JW, Marek CL (2006). Bisphosphonate induced osteochemonecrosis of the jaws: an ounce of prevention may be worth a pound of cure. Spec Care Dentist 26 : 8 12.
27. Hewitt C, Farah CS (2007). Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 36 : 319 328.
28. Jeffcoat MK (2006). Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 21 : 349 353.
29. Keating GM, Scott LJ (2007). Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs 67 : 793 804.
30. Keim RG (2006). Bisphosphonates in orthodontics. J Clin Orthod 40 : 403 404.
31. Khosla S, Burr D, Cauley J et al (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22 : 1479 1491.
32. Landis BN, Dojcinovic I, Richter M, Hugentobler M (2007). Osteonecrosis of the jaws: maxillofacial recommendations for bisphosphonate prescribers. J Intern Med 261 : 101 102.
33. Leite AF, Figueiredo PT, Melo NS et al (2006). Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 : 14 21.
34. Liberman UA (2006). Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. Drugs Aging 23 : 289 298.
35. Lipton A, Theriault RL, Hortobagyi GN et al (2000). Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88 : 1082 1090.
36. Marx RE, Sawatari Y, Fortin M, Broumand V (2005). Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 : 1567 1575.
37. Marx RE, Cillo JE Jr., Ulloa JJ (2007). Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 : 2397 2410.
38. Mavrokokki T, Cheng A, Stein B, Goss A (2007). Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 : 415 423.
39. McLeod NM, Davies BJ, Brennan PA (2007). Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner. Br Dent J 203 : 641 644.
40. ® (alendronate sodium) and rare cases of osteonecrosis of the jaw. Available at: http://www.merck.com/newsroom/press-releases/product/fosamax-statement.html (accessed 4 June 2008).
41. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005). Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136 : 1658 1668.
42. Migliorati CA, Siegel MA, Elting LS (2006). Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 : 508 514.
43. Montefusco V, Gay F, Spina F et al (2008). Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49 : 2156 2162.
44. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P (2007). A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29 : 1548 1558.
45. Pickett FA (2006). Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines. J Dent Hyg 80 : 10.
46. Regev E, Lustmann J, Nashef R (2008). Atraumatic teeth extraction in bisphosphonate-treated patients. J Oral Maxillofac Surg 66 : 1157 1161.
47. Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R (2007). Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop 131 : 321 326.
48. Ripamonti CI, Maniezzo M, Campa T et al (2009). Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20 : 137 145.
49. Ruggiero SL, Drew SJ (2007). Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86 : 1013 1021.
50. Russell RG, Croucher PI, Rogers MJ (1999). Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9 : s66 s80.
51. Sachs HC (2008). One year post exclusivity adverse event review: alendronate. Center for drug evaluation and research, food and drug administration. Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/ 2004-4067s1-07-Sachs%202%20Final.pdf (accessed 4 June 2008).
52. Sarathy AP, Bourgeois SL Jr., Goodell GG (2005). Bisphosphonate- associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 31 : 759 763.
53. Silverman SL, Landesberg R (2009). Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 122 : S33 S45.
54. Valderhaug J, Jokstad A, Ambjørnsen E, Norheim PW (1997). Assessment of the periapical and clinical status of crowned teeth over 25 years. J Dent 25 : 97 105.
55. Van den Wyngaert T, Huizing MT, Vermorken JB (2007). Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 19 : 315 322.
56. Weitzman R, Sauter N, Eriksen EF et al (2007). Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Crit Rev Oncol Hematol 62 : 148 152.
57. Woo SB, Hellstein JW, Kalmar JR (2006). Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 : 753 761.
58. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S (2007). Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18 : 1363 1370.
59. Zahrowski JJ (2007). Bisphosphonate treatment: an orthodontic concern calling for a proactive approach. Am J Orthod Dentofacial Orthop 131 : 311 320.